Vertex Pharmaceuticals Inc
Close on Nov 20, 2026Market cap $130.54BP/E 30.0Yield –
Vertex Pharmaceuticals Executive Compensation (DEF 14A) by Year
Executive Compensation (DEF 14A) — CEO Summary Compensation Table (SCT) total ($M) ($M)
Vertex Pharmaceuticals Executive Compensation (DEF 14A): $21.1M in FY2025, down 1.9% from a year earlier.
Where the FY2025 figure comes from
“|| 2025 | $ 21,144,261 | $ 38,218,069 | $ 7,727,328 | $ 13,414,754 | $ 191.83 | $ 124.75 | $ 4.0 Billion | $ 11.97 Billion”
Source: Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗
Reported in DEF 14A Proxy Statements (Executive Compensation & Pay Versus Performance).
annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Executive Compensation (DEF 14A) — CEO Summary Compensation Table (SCT) total ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 21.1 | -1.9% | Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗ |
| FY2024 | Dec 31, 2024 | 21.5 | +4.6% | Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗ |
| FY2023 | Dec 31, 2023 | 20.6 | +29.8% | Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗ |
| FY2022 | Dec 31, 2022 | 15.9 | +4.3% | Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗ |
| FY2021 | Dec 31, 2021 | 15.2 | +65.9% | Proxy Statement (DEF 14A) (vrtx-20260402.htm, filed 2026-04-02) ↗ |
| FY2020 | Dec 31, 2020 | 9.16 | – | Proxy Statement (DEF 14A) (lvrtx2021_def14a.htm, filed 2021-04-08) ↗ |
Breakdown
What makes up executive Compensation (DEF 14A)
- Pay Versus Performance (PVP) — CEO Compensation Actually Paid (CAP) ($M)38.2 · FY2025
- Pay Versus Performance (PVP) — Non-CEO Named Executive Officers (NEOs) average SCT total ($M)7.73 · FY2025
- Pay Versus Performance (PVP) — Non-CEO NEOs average Compensation Actually Paid (CAP) ($M)13.4 · FY2025
- CEO Pay Ratio — Median employee annual total compensation ($)264,487 · FY2025
- CEO Pay Ratio — CEO to median employee pay ratio (x:1)80.00 · FY2025
- Pay Versus Performance — Value of initial fixed $100 investment in VRTX cumulative TSR ($)192 · FY2025
- Pay Versus Performance — Value of initial fixed $100 investment in Nasdaq Biotechnology Index peer TSR ($)125 · FY2025
Cite this data
StockData. (2026). Vertex Pharmaceuticals Executive Compensation (DEF 14A) ($M), annual FY2020–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/ceo-sct-total
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.
See a number that looks wrong?